Philip A. Pizzo, M.D.

Publication Details

  • EVALUATION OF NEW ANTIINFECTIVE DRUGS FOR THE TREATMENT OF FEBRILE EPISODES IN NEUTROPENIC PATIENTS CLINICAL INFECTIOUS DISEASES Hughes, W. T., Pizzo, P. A., Wade, J. C., Armstrong, D., Webb, C. D., Young, L. S. 1992; 15: S206-S215

    Abstract:

    The use of empirical antimicrobial therapy has significantly reduced the morbidity and mortality associated with untreated infections in febrile neutropenic patients. This guideline describes clinical trials of the safety and efficacy of new antimicrobial drugs in this population of patients. Fever and neutropenia should be precisely defined in each protocol. Patients should be randomized to treatment with a new or active-control drug regimen, stratified on the basis of type of cancer and age, and treated until resolution--as defined in the protocol--is attained. Outcome should be assessed both for cases with a defined microbial etiology and for those without. Final microbiological outcome is important for cases with identified pathogens, but clinical outcome is paramount.

    View details for Web of Science ID A1992JX58600027

    View details for PubMedID 1477232

Stanford Medicine Resources:

Footer Links: